ArriVent Biopharma Launches with Up To $150M in Series A Financing and Strategic Licensing Agreement for Clinical-Stage Oncology Asset Funds will be used to build ArriVent’s portfolio of innovative in-licensed assets for global development Company enters first licensing agreement with Allist Pharma, granting ArriVent ex-China...